Tag: the war on (some) drugs

Pennsylvania Lawmaker Files Bill To Protect Medical Marijuana Patients From DUI Charges

A Pennsylvania lawmaker has reintroduced a bill meant to protect medical marijuana patients from facing DUI charges when there is no proof they are actually impaired behind the wheel.

Rep. Chris Rabb (D) filed the legislation and circulated a cosponsorship memo this week, urging his colleagues to join him in this latest effort to enact the reform.

The memo says that, since the state legalized medical marijuana, many patients have “shared their horror stories about being arrested and convicted of driving under the influence of cannabis without any proof of impairment.”

“That is why this legislation…is being introduced yet again, as the current law must be amended to allow responsible drivers who are also medical cannabis patients to operate a motor vehicle legally,” Raab wrote, emphasizing that the legislation “does not extend to any illegal cannabis use–nor does it protect impaired drivers.”

The bill would amend the current state statute to make it so the presence of cannabis metabolites in a drug test alone could not be used as evidence of impaired driving if the person is a registered medical marijuana patient.

However, that protection would not extend to those who hold a commercial driver’s license.

Keep reading

UN Drug Commission Votes To Ban Previously Uncontrolled Marijuana Compound, With U.S. Abstaining

The United Nations (UN) Commission on Narcotic Drugs (CND) voted this week to ban the marijuana component hexahydrocannabinol (HHC) under an international treaty, with every country present except the United States casting a vote in favor of placing the substance under Schedule II of the 1971 Convention on Psychotropic Substances.

The U.S., for its part, abstained. In a statement afterward, officials said they were “unable to vote” on the HHC proposal as well as another being voted on that placed the drug carisoprodol under Schedule IV.

“While the United States supports the use of the international scheduling system to make scientifically-informed decisions about international drug control, we were unable to vote on the proposals,” the statement said. “Nevertheless, both of these substances are already controlled in the United States, at levels that will allow the United States to meet its international obligations arising from the CND’s decisions today.”

The statement gave no further information explaining why the U.S. was unable to cast those votes.

CND also voted to regulate four other non-cannabis compounds under international law.

In a social media post, the UN Office on Drugs and Crime (UNODC) called the actions “critical decisions on the control of harmful substances.”

“These decisions shape drug policies, law enforcement and public health worldwide,” the body said.

Keep reading

New Mexico Senate Passes Bill To Create Psilocybin Therapy Program

The New Mexico Senate has passed a bill to establish a therapeutic psilocybin program in the state.

After clearing three separate committees over the past month, the legislation from Sen. Jeff Steinborn (D) was approved by the full chamber in a 33-4 vote on Wednesday, sending it to the House of Representatives.

If enacted, the Medical Psilocybin Act would allow patients with certain qualifying conditions to access the psychedelic and use it under the guidance of a licensed healthcare provider.

“I have come to know and become friends with combat veterans, physicians, providers and even practitioners who serve patients dealing with end-of-life anxiety,” Steinborn said on the floor. “This bill seeks to create a carefully calculated, thoughtful and patient program that would be developed by the Department of Health…to allow patients in a medical setting.”

“This is very different from cannabis. It could only be administered in a medical setting by licensed providers,” he said. “Sometimes it can be as effective as one treatment, and people can have long-term relief from that that they’re dealing with.”

The sponsor added that “we recognize the important need of continuing to do research, so we have the best program here, where the Department of Health is making the best available science decisions on medical setting, dosage, et cetera.”

Sen. Jay Block (R), a veteran himself, said that while he was initially “adamantly opposed” to the proposed reform, he has come to better understand the issue as a “right to try” policy for those with serious mental health conditions. He teared up during the Senate debate, recognizing veterans and others who he’s since learned benefitted from the psychedelic.

An amendment from Sen. Katy Huhigg (D) was adopted on the floor to clarify that the use of federally approved psilocybin would be allowed under the state law, but that such products would not be further regulated by the state.

The amendment would also remove a requirement that the department develop “qualifying conditions” for producers and clinicians, add a health care provider to the advisory board that would be created by the bill and strike language the sponsor described as “redundant.”

The measure says its purpose “is to allow the beneficial use of psilocybin in a regulated system for alleviating qualified medical conditions,” including major treatment-resistant depression, PTSD, substance use disorders and end-of-life care. The state Department of Health would be able to approve additional conditions.

Therapy would consist of a preparation session, an administration session and a follow-up integration session.

The state health department would be responsible for establishing guidelines around training for clinicians and producers, including dosage, approved settings for administration, production and storage protocols and other best practices. State officials would also license producers to grow mushrooms and process psilocybin.

Synthetic psilocybin and synthetic analogs of the substance would not be allowed under the proposal.

Keep reading

Missouri Senators Approve Bill To Legalize Psilocybin Therapy For Veterans And Sex Trafficking Survivors

Missouri senators have advanced a bill to allow military veterans and survivors of sex trafficking who have certain mental health conditions to legally access psilocybin therapy.

The Senate Families, Seniors and Health Committee approved the legislation from Sen. Stephen Webber (D) on Wednesday. A similar House bill focused on the psychedelic moved through a separate panel earlier this month.

In addition to being 21 or older, a military veteran or sex trafficking survivor and enrolled in a clinical trial, participants in the proposed program would need to have PTSD, major depressive disorder, a substance use disorder or be in end-of-life care.

They would also need to provide documentation to the state Department of Mental Health about the treating physician, facilitator and location and time of use.

Further, use of psilocybin would be limited to 150 mg during a 12-month period.

The bill also authorizes the state Department of Health to provide up to $3 million worth of grants to support research on the therapeutic potential of psilocybin.

Keep reading

Nevada Senators Take Up Resolution Calling On Congress To Reschedule Psychedelics And Streamline Research

Nevada senators took up a joint resolution on Tuesday that calls on Congress to reschedule certain psychedelics, provide protections for individuals using the substances in compliance with state law and streamline research.

As the Nevada legislature pushes forward with psychedelics reform, the Senate Legislative Operations and Elections Committee discussed the resolution from Sen. Rochelle Nguyen (D), hearing testimony from experts in the field.

“It is very much a grassroots, bipartisan issue. It is a Nevada issue,” Nguyen said in her opening remarks. “This is such an important issue. And this may seem like it’s an innocuous [resolution] where we’re sending a letter, but it is super important that we as a state send a message to the federal government—send a message to Washington, D.C.—that we need to start helping our community.”

“We have a mental health crisis. I don’t think you go into a committee room where you don’t hear about this,” she said. “This is just another solution to a problem that we have across our state.”

Keep reading

Atlanta’s Decriminalization Of Marijuana ‘Led To A Reduction In Violent Crime,’ New Research Shows

A new study on Atlanta’s move to decriminalize marijuana concludes that, contrary to warnings from some critics, the policy change in fact led to a decrease in violent crime as police turned their attention to more urgent matters.

The research looks at crime surrounding the city’s 2017 reduction of penalties around the simple possession of cannabis. Prior to the change, possession of up to an ounce of marijuana was punishable by up to a year in jail and a $1,500 fine. Afterward, that fell to a maximum $75 fine civil fine, with no possibility of jail time.

While some warned that loosening penalties would lead to a rise in crime rates, researchers observed the opposite.

“Our findings suggest that decriminalization led to a reduction in violent crime,” the new report says, “likely due to police reallocating resources from marijuana enforcement to violent crime prevention.”

To arrive at that conclusion, authors examined agency-level crime data from 2015 through 2018 from Federal Bureau of Investigation (FBI) Uniform Crime Reports, which included information from nearly all Georgia cities with populations over 25,000. They then compared crime rates between Atlanta and other control cities that did not decriminalize marijuana.

Relative to those control cities, the “estimated effect” of decriminalization in Atlanta was “about 20 fewer violent crimes per 100,000 people per month,” the analysis found. That’s a 19.7 percent reduction from the pre-decriminalization average.

“Our analysis finds that violent crime in Atlanta declined relative to control agencies following marijuana decriminalization, with results robust to alternative estimation methods, event studies, and placebo tests,” the report concludes. “Our estimates suggest that decriminalization led to a 20% reduction in violent crime rates relative to pre-policy levels.”

The paper says the findings align with claims from Atlanta Police Department (APD) shortly after decriminalization that officers would “focus…on violent crime and crimes that truly affect people—things that endanger lives.”

“We want to fill jails with armed robbers, rapists, burglars, home invaders—we do not want to fill the jails with pot smokers. That’s the bottom line,” APD Public Affairs Director Carlos Campos said at the time, the study notes.

Atlanta’s decreases in violent crime, the study’s authors noted, “align with APD’s stated policy shift, as department leaders emphasized reallocating resources to violent crime enforcement.”

“Importantly, this decline was not offset by crime displacement in neighboring counties,” they added.

Keep reading

Drugs taken by millions in US can cause ‘deviant’ sexual behavior including pedophilia — but patients aren’t warned by doctors

A class of drugs commonly used to treat movement disorders like Parkinson’s disease and restless leg syndrome is pushing people into risky sexual behavior. 

Patients taking dopamine agonists say the drugs have triggered uncontrollable impulses, including flashing, sex addiction and even pedophilia — leaving them struggling with feelings of shame and confusion.

Reports reviewed by the BBC suggest drugmaker GSK has known about the risk of so-called “deviant” sexual behavior since 2003, yet patients claim their doctors continue to fail to warn them about these potentially devastating side effects.

Dopamine agonists mimic dopamine, a key brain chemical that controls movement and is activated by pleasure. However, these drugs can overstimulate feelings of pleasure while dulling the brain’s ability to recognize the consequences of our actions.

This can lead to impulse control disorders, with studies showing 13% to 24% of Parkinson’s patients on dopamine agonists develop them. While a warning about these risky behaviors is listed alongside common side effects like nausea and insomnia, research suggests they often go unnoticed or undiagnosed.

In the US, the American Academy of Sleep Medicine recommends the drugs only be used for short-term treatment, such as end-of-life care.

Keep reading

There’s Plenty Of Evidence Medical Marijuana Can Treat Female Orgasm Difficulty, So Why Are Some States Saying No?

While numerous studies have consistently shown that cannabis can treat female orgasm difficulty/disorder, also known as FOD, so far only a few states have recognized it as a qualifying condition for medical marijuana. Others appear to be holding it to a higher standard than other conditions, revealing a potential bias against women.

This bias may be the result of misinformation or lack of education about FOD, a serious public health condition that affects the health of up to 41 percent of women worldwide. The bias may also reflect an unwillingness to acknowledge FOD, despite testimony from women who successfully treated the condition with cannabis, letters of support from doctors who recommend cannabis for it, evidence of its serious health impacts and scientific studies showing cannabis can treat it.

In 2024, advocates—myself included—petitioned 11 U.S. states to add FOD as a qualifying condition. While some petitions are still pending, so far two states have officially approved the requests: Connecticut and Illinois.

Illinois Director of Public Health Dr. Sameer Vodra stated the following in his order approving FOD as a qualifying condition:

“After fully considering the matters raised in the petition, as well as reviewing research pertinent to the condition termed Female Orgasmic Disorder, a condition where a (natal) female has difficulty reaching orgasm. There are multiple types and causes,) there is sufficient evidence to confidently evaluate the effect of cannabis as a treatment for Female Orgasmic Disorder. Literature review and survey data support that cannabis can offer benefits to women who have “female orgasm difficulties or dysfunction.”

In New Mexico, the state’s Medical Cannabis Advisory Board approved adding FOD as a qualifying condition last fall, with the reform set to take effect upon official approval from the secretary of health.

The states of Colorado, New Jersey and Pennsylvania, meanwhile, have acknowledged receipt of the petitions to add FOD as a qualifying condition, and public hearing dates are now pending.

Yet despite scientific evidence and approvals in some jurisdictions, five states denied adding FOD as a qualifying condition with medical cannabis: Arkansas, Maryland, Mississippi, Ohio and Oregon.

Keep reading

Federal Memo From National Cancer Institute Lists Marijuana As ‘Controversial ‘Topic That Needs Special Approval Before Publication

“Marijuana” is one of nearly two dozen “controversial or high-profile topics” that staff and researchers at the National Cancer Institute (NCI) are required to clear with higher-ups before writing about, according to a newly leaked memo from within the federal agency.

The government directive puts marijuana and opioids on a list along with vaccines, COVID-19, fluoride, measles, abortion, autism, diversity and gender ideology and other issues that are believed to be personal priorities of Health and Human Services Secretary Robert F. Kennedy Jr. and President Donald Trump.

NCI is part of the National Institutes of Health (NIH), which itself is part of the Department of Health and Human Services (HHS).

Prior to publishing anything on the specified topics, NCI staff are required to send the materials to an agency clearance team, says the new memo, first reported by ProPublica.

“Depending on the nature of the information, additional review and clearance by the NCI director, deputy directors, NIH, and HHS may be required,” it advises staff. “In some cases, the material will not need further review, but the NCI Clearance Team will share it with NCI leadership, NIH, and/or HHS for their awareness.”

It notes that staff “do not need to share content describing the routine conduct of science if it will not get major media attention, is not controversial or sensitive, and does not touch on an administration priority,” according to the ProPublica report.

The investigative news outlet says the directive “was circulated by the institute’s communications team, and the content was not discussed at the leadership level,” adding that “it is not clear in which exact office the directive originated.”

Experts said the policy could have a chilling effect, slowing publication of important findings and pushing researchers to censor their work.

Keep reading

New Mexico House And Senate Lawmakers Approve Bills To Strengthen Employment Protections For Medical Marijuana Patients

Another New Mexico House committee has passed a bill that would further protect medical marijuana patients in the state from being penalized at work for off-duty use of cannabis. And a Senate companion version of the legislation also moved through a panel in that chamber.

On Friday, the House Judiciary Committee approved the proposal from House Majority Floor Leader Reena Szczepanski (D) in a 7-3 vote. This comes almost a month after an earlier committee advanced the proposal.

Meanwhile, the Senate companion bill—sponsored by Sens. Linda López (D) and Shannon Pinto (D)—separately passed the Senate Health and Public Affairs Committee by a tally of 6-3.

Under the legislation, employees could not be considered “impaired” by cannabis if a test is based solely on the presence of THC metabolites.

The measures would further prohibit random drug testing for marijuana, though patients could be screened if there’s reasonable suspicion that cannabis was used on the clock resulting in “significant damage to property.”

At the prior House committee meeting, members adopted a minor amendment that replaces a line in the bill that had said a “drug test for cannabis shall be reviewed by a medical review officer who shall determine if the reason for a positive test has a legitimate medical explanation.”

Under the new language, the bill now says that an employer “shall follow the cannabis impairment guidelines when testing for cannabis impairment.”

The legislation was further amended in the House Judiciary Committee to prevent the use of a positive cannabis test as evidence in civil cases “exposing the employer to liability arising out of the employee’s on-duty conduct.”

The measures also stipulate that the state Department of Health must “assist the workforce solutions department in developing cannabis impairment guidelines that are based on the most reliable research- or evidence-based cannabis impairment indicators, including the evaluation of physical symptoms and psychomotor and cognitive performance.”

“The workforce solutions department shall inform private employers of this section and provide information related to the most recent advances in testing protocols for determining cannabis impairment,” they say. “The department of finance and administration shall disseminate the cannabis impairment guidelines to state agencies and political subdivisions of the state.”

Keep reading